In This Article : [Yahoo! Finance]
I-MAB - American Depositary Shares (IMAB)
Company Research
Source: Yahoo! Finance
The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025 ; a 40-patient dose expansion study is now underway with data expected in early 2026 Cash balance of $184.4 million (as of September 30, 2024 ), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating model ROCKVILLE, MD Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today highlighted its strategic outlook for 2025 and a re-prioritization of resources, with a focus on advancing its lead program, givastomig, a CLDN18.2 x 4-1BB bispecific antibody, targeting first-line metastatic gastric cancers, with further potential in other solid tumors. (PRNewsfoto/I-Mab Biopharma) "I-Mab made ex
Show less
Read more
Impact Snapshot
Event Time:
IMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMAB alerts
High impacting I-MAB - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMAB
News
- I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical ProgramPR Newswire
- I-Mab Leads Our Spotlight On 3 US Penny Stocks [Yahoo! Finance]Yahoo! Finance
- I-Mab to Participate at the Piper Sandler Healthcare ConferencePR Newswire
- I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- I-Mab Reports Third Quarter 2024 Results [Yahoo! Finance]Yahoo! Finance
IMAB
Earnings
- 11/14/24 - Miss
IMAB
Analyst Actions
- 11/15/24 - HC Wainwright
IMAB
Sec Filings
- 1/6/25 - Form 6-K
- 12/3/24 - Form 6-K
- 11/14/24 - Form 6-K
- IMAB's page on the SEC website